Market Trends of Sarcopenia Treatment Industry
Protein Supplement Anticipated to Show Considerable Growth During the Forecast Period
Protein is a critical macronutrient for the maintenance of normal bodily functions. Daily protein intake varies by age, sex, and degree of daily activity but is essential to maintaining muscle mass and strength throughout an individual's lifespan. Therefore, increasing protein intake in the diet prevents the loss of muscle mass, thus driving the market.
The growing research and development activities are helping to identify the protein dosage required to fulfill the protein deficiency in the body, and treating sarcopenia is likely to drive segment growth. For instance, an article published in March 2022 stated that protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries.
Furthermore, according to the study published in March 2022 in PubMed, protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries. Hence, studies demonstrating the use of protein supplements in sarcopenia are expected to drive market growth over the forecast period. Moreover, strategic activities by the key players and awareness regarding the importance of sarcopenia treatments are expected to boost market growth. For instance, in July 2022, World Sarcopenia Day was celebrated worldwide, and it serves as an opportunity to raise awareness and knowledge for the prevalent disease, sarcopenia. Hence, the growing awareness among consumers regarding the diseases would increase the demand for protein supplements and products.
Several companies invest in research and development activities to provide innovative protein powder products catering to consumers’ preferences. For instance, the availability of protein powders that are plant-based, lactose-free, or specifically designed for women or athletes has increased in recent years. In October 2022, Tata Consumer Products (TCP), a part of Tata Group, expanded into the health supplements segment by introducing ‘Tata GoFit,’ a plant-based protein powder product designed for health-conscious women.
Hence, the studied segment is expected to witness significant growth over the forecast period due to the increased research and development and the key players' strategic activities.
North America Anticipated to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant position in the sarcopenia treatment market, owing to the presence of developed healthcare facilities and technological advancements that are likely to fuel the growth of the sarcopenia treatment market during the forecast period.
Furthermore, an increase in the geriatric population in North America is expected to bolster market growth over the forecast period. For instance, according to the Statistics Canada July 2022 update, as of July 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Thus, the geriatric population is more prone to sarcopenia and other muscle-related diseases; the rise in the geriatric population is expected to increase the need for sarcopenia treatment, driving the market growth over the forecast period.
Furthermore, various clinical studies are widely conducted in the North American region to demonstrate the efficacy of supplements in sarcopenia treatments. For instance, in April 2022, the University of Arkansas sponsored a clinical trial to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), to determine the state of muscle health. For that purpose, trial subjects were given 10 g of a commercially available nutritional supplement for sarcopenia. Hence, an increase in such clinical studies demonstrating the clinical outcome of supplements to treat sarcopenia may result in the launch of new supplements and thus may contribute to the growth of the studied market in the region.
Moreover, various government initiatives support research and development of sarcopenia treatments, further contributing to market growth. For instance, according to the article published in February 2022 in PubMed, the United States Department of Health and Human Services was one of the leading funding organizations that sponsored 1,604 sarcopenia-related articles. The United States is a significant country in the North American region that contributes more toward sarcopenia-related research and development. This increased research is anticipated to lead to various innovations in the country, driving the growth of the sarcopenia treatment market in the country.
Thus, due to the increase in the geriatric population and the rise in strategic activities by the government and key players, North America is expected to witness significant growth over the forecast period.
